PMV Pharmaceuticals’ New Targeted Therapy Shows 48% Response Rate in a Phase 2  Ovarian Cancer Trial

PMV Pharmaceuticals’ New Targeted Therapy Shows 48% Response Rate in a Phase 2 Ovarian Cancer Trial

An investigational oral therapy designed to restore the function of a mutated tumor-suppressor protein has demonstrated clinical activity in patients with advanced ovarian cancer who have limited treatment options.

On November 20, 2026, PMV Pharmaceuticals announced updated results from the pivotal Phase 2 portion of the PYNNACLE trial, evaluating rezatapopt (PC14586) in patients with advanced solid tumors harboring the TP53 Y220C mutation.

The findings, presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, showed a 48% confirmed overall response rate (ORR) in the primary analysis population of 65 patients with platinum-resistant or refractory ovarian cancer. The median duration of response reached 10.4 months.

Across all tumor cohorts, the company reported a 36% response rate among 168 evaluable patients, supporting further investigation of mutation-specific p53 reactivation.

Based on these findings, PMV Pharmaceuticals plans to submit a New Drug Application (NDA) seeking accelerated FDA approval in the first quarter of 2027.

Targeting One of Cancer’s Most Commonly Mutated Genes

The TP53 gene, which encodes the p53 tumor-suppressor protein, is among the most frequently altered genes in human cancers. Mutations can impair the protein’s ability to regulate cell growth, respond to DNA damage, and prevent uncontrolled cell division.

Despite decades of research, directly targeting mutant p53 has remained challenging.

Rezatapopt takes a mutation-specific approach. Rather than targeting all TP53 alterations, it is designed to bind selectively to the p53 Y220C mutant protein and stabilize its structure, with the aim of restoring tumor-suppressor activity.

The treatment is an orally administered small molecule given once daily, potentially offering a chemotherapy-free approach for patients whose tumors carry this specific molecular alteration.

Previous research, including Phase 1 PYNNACLE findings covered by OncoDaily, provided early evidence of clinical activity across several tumor types.

The latest Phase 2 results provide a larger efficacy dataset, particularly in platinum-resistant ovarian cancer.

PYNNACLE Phase 2 Trial Shows 48% Response Rate in Ovarian Cancer

The ongoing PYNNACLE trial (NCT04585750) is a multicenter Phase 1/2 study evaluating rezatapopt in patients with advanced solid tumors carrying the TP53 Y220C mutation.

The Phase 2 portion is a single-arm, registrational basket study involving approximately 70 clinical sites and five tumor cohorts.

At the September 4, 2026, data cutoff, the study included 180 patients in the safety population and 168 in the efficacy population.

Among patients with ovarian cancer, 93% had high-grade serous disease and 97% had platinum-resistant or refractory disease. They had received a median of four prior lines of systemic therapy.

In the primary analysis population of 65 patients with platinum-resistant or refractory ovarian cancer who had previously received standard-of-care treatment, investigator-assessed results according to RECIST v1.1 showed:

  • Confirmed overall response rate: 48% (31 of 65 patients)
  • Complete responses: 1 patient
  • Partial responses: 30 patients
  • Median duration of response: 10.4 months
  • Disease control rate: 83%

These results suggest antitumor activity in a heavily pretreated population, although the single-arm design does not establish comparative efficacy against existing treatments.

Rezatapopt Demonstrates Activity Across Multiple Solid Tumors

Beyond ovarian cancer, responses were observed in patients with several other tumor types harboring TP53 Y220C mutations.

Across the entire efficacy population of 168 patients, PMV Pharmaceuticals reported:

  • Overall response rate: 36% (61/168), including four unconfirmed partial responses
  • Median duration of response: 8.1 months
  • Median time to response: 1.3 months

Response rates by tumor cohort were:

  • Ovarian cancer: 45% (45/101)
  • Endometrial cancer: 45% (5/11)
  • Lung cancer: 21% (4/19)
  • Breast cancer: 17% (3/18)
  • Other solid tumors: 21% (4/19)

The ovarian cancer cohort response rate included four unconfirmed partial responses; the other listed non-ovarian cohort response rates were confirmed.

Confirmed responses were identified across eight tumor types, including head and neck, colorectal, gallbladder, and ampullary cancers, in patients with TP53 Y220C-mutated, KRAS wild-type tumors.

Although some cohorts were relatively small, the findings provide additional evidence that targeting this specific molecular alteration may have activity beyond a single cancer type.

PMV Pharmaceuticals' New Targeted Therapy Shows 48% Response Rate in a Phase 2 Ovarian Cancer Trial

Early ctDNA Changes Provide Evidence of Molecular Activity

The study also evaluated circulating tumor DNA (ctDNA) as a potential marker of treatment activity.

Among 50 patients with available ctDNA data, 90% (45 patients) experienced at least a 50% reduction in the variant allele frequency of TP53 Y220C within three to six weeks of beginning rezatapopt.

These molecular changes are consistent with activity against the intended target and provide an additional biological signal alongside radiographic tumor responses.

However, further research is needed to determine whether early ctDNA changes can reliably predict longer-term treatment outcomes.

Safety Findings From the PYNNACLE Trial

Rezatapopt was administered at a dose of 2,000 mg orally once daily.

Treatment-related adverse events were predominantly Grade 1 or 2. The most frequently reported events, each occurring in more than 15% of patients, included:

  • Nausea and vomiting
  • Fatigue
  • Increased blood creatinine
  • Elevated AST and ALT levels
  • Anemia

Individual Grade 3 treatment-related adverse events occurred at rates of 7.2% or lower.

Eleven patients (6%) discontinued treatment because of treatment-related adverse events, including seven patients with ovarian cancer.

The company reported that laboratory abnormalities were generally transient and reversible. Continued safety monitoring remains important as the investigational treatment advances toward regulatory review.

Investigators Highlight the Need for New Treatment Options

Alison M. Schram, MD, Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE study investigator, presented the updated findings at ENA 2026.

Commenting on the results, she stated:

“Patients with platinum-resistant ovarian cancer who have progressed on standard therapies have few treatment options.”

The findings are particularly relevant because platinum resistance remains a major challenge in recurrent ovarian cancer, where treatment choices often become more limited following multiple lines of therapy.

The observed responses also raise questions about how molecular testing for specific TP53 variants could inform future treatment selection.

Importantly, rezatapopt targets the Y220C alteration specifically, meaning that its potential application cannot be generalized to all patients with TP53-mutated cancers.

What Comes Next for Rezatapopt?

PMV Pharmaceuticals intends to seek accelerated FDA approval for rezatapopt in patients with TP53 Y220C-mutated platinum-resistant or refractory ovarian cancer, with an NDA submission planned for the first quarter of 2027.

The FDA has previously granted rezatapopt Fast Track designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug designation for TP53 Y220C-positive ovarian, fallopian tube, and primary peritoneal cancers.

The regulatory submission will be an important next step, but rezatapopt remains investigational and has not received FDA marketing approval.

The findings also have important limitations. PYNNACLE is a single-arm study, and the available results do not establish a survival advantage or demonstrate superiority over currently available therapies.

Nevertheless, the updated results provide evidence that pharmacologically restoring the function of a specific mutant p53 protein can produce measurable clinical responses.

For patients with heavily pretreated ovarian cancer carrying TP53 Y220C, the next questions are whether these responses translate into meaningful longer-term outcomes and how this approach might fit into future treatment strategies.

Read further on OncoDaily: OCRF and News Corp Australia Launch “Over It” Campaign to Close the Ovarian Cancer Survival Gap
PMV Pharmaceuticals' New Targeted Therapy Shows 48% Response Rate in a Phase 2 Ovarian Cancer Trial